{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:20:13Z","timestamp":1791534013348,"version":"4.3.4"},"reference-count":40,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","award":["N\/A (funded study [formerly by Viela Bio\/MedImmune"],"award-info":[{"award-number":["N\/A (funded study [formerly by Viela Bio\/MedImmune"]}],"id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate relationships between serum neurofilament light chain (sNfL), ubiquitin C-terminal hydrolase L1 (sUCHL1), tau (sTau) and glial fibrillary acidic protein (sGFAP) levels and disease activity\/disability in neuromyelitis optica spectrum disorder (NMOSD), and the effects of inebilizumab on these biomarkers in N-MOmentum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>N-MOmentum randomised participants to receive inebilizumab or placebo with a randomised controlled period (RCP) of 28 weeks and an open-label follow-up period of \u22652 years. The sNfL, sUCHL1, sTau and sGFAP were measured using single-molecule arrays in 1260 scheduled and attack-related samples from N-MOmentum participants (immunoglobulin G (IgG) autoantibodies to aquaporin-4-positive, myelin oligodendrocyte glycoprotein-IgG-positive or double autoantibody-negative) and two control groups (healthy donors and patients with relapsing\u2013remitting multiple sclerosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The concentration of all four biomarkers increased during NMOSD attacks. At attack, sNfL had the strongest correlation with disability worsening during attacks (Spearman R\n                      <jats:sup>2<\/jats:sup>\n                      =0.40; p=0.01) and prediction of disability worsening after attacks (sNfL cut-off 32\u2009pg\/mL; area under the curve 0.71 (95% CI 0.51 to 0.89); p=0.02), but only sGFAP predicted upcoming attacks. At RCP end, fewer inebilizumab-treated than placebo-treated participants had sNfL&gt;16\u2009pg\/mL (22% vs 45%; OR 0.36 (95% CI 0.17 to 0.76); p=0.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with sGFAP, sTau and sUCHL1, sNfL at attack was the strongest predictor of disability worsening at attack and follow-up, suggesting a role for identifying participants with NMOSD at risk of limited post-relapse recovery. Treatment with inebilizumab was associated with lower levels of sGFAP and sNfL than placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT02200770\">NCT02200770<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2022-330412","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:24:02Z","timestamp":1684848242000},"page":"757-768","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder"],"prefix":"10.1136","volume":"94","clinical-trial-number":[{"clinical-trial-number":"nct02200770","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct02200770","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-9210","authenticated-orcid":false,"given":"Orhan","family":"Aktas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-8419","authenticated-orcid":false,"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cimbora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A","family":"Cree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"2024102910301110000_94.9.757.1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515620934"},{"key":"2024102910301110000_94.9.757.2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","article-title":"Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease","volume":"3","author":"Fujihara","year":"2012","journal-title":"Clin Exp Neuroimmunol"},{"key":"2024102910301110000_94.9.757.3","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000254502.87233.9a"},{"key":"2024102910301110000_94.9.757.4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024102910301110000_94.9.757.5","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001034","article-title":"Molecular level characterization of circulating aquaporin-4 antibodies in neuromyelitis optica spectrum disorder","volume":"8","author":"Li","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301110000_94.9.757.6","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0766-7","article-title":"Complement-independent bystander injury in AQP4-igG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity","volume":"7","author":"Duan","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2024102910301110000_94.9.757.7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/brain\/awac079","article-title":"A new form of axonal pathology in a spinal model of neuromyelitis optica","volume":"145","author":"Herwerth","year":"2022","journal-title":"Brain"},{"key":"2024102910301110000_94.9.757.8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fimmu.2018.01438","article-title":"Aquaporin-4 autoantibodies from neuromyelitis optica spectrum disorder patients induce complement-independent immunopathologies in mice","volume":"9","author":"Yick","year":"2018","journal-title":"Front Immunol"},{"key":"2024102910301110000_94.9.757.9","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301110000_94.9.757.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13167-016-0063-5","article-title":"Current status of biomarker research in neurology","volume":"7","author":"Polivka","year":"2016","journal-title":"EPMA J"},{"key":"2024102910301110000_94.9.757.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.150698"},{"key":"2024102910301110000_94.9.757.12","doi-asserted-by":"crossref","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"2024102910301110000_94.9.757.13","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"2024102910301110000_94.9.757.14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26067"},{"key":"2024102910301110000_94.9.757.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.3.402"},{"key":"2024102910301110000_94.9.757.16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.dadm.2019.08.009","article-title":"The diagnostic performance of neurofilament light chain in CSF and blood for alzheimer\u2019s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"11","author":"Forgrave","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"2024102910301110000_94.9.757.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010084"},{"key":"2024102910301110000_94.9.757.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"2024102910301110000_94.9.757.19","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001051","article-title":"Increased serum neurofilament light and thin ganglion cell-inner plexiform layer are additive risk factors for disease activity in early multiple sclerosis","volume":"8","author":"Lin","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301110000_94.9.757.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-013-9634-4"},{"key":"2024102910301110000_94.9.757.21","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00204","article-title":"Role of tau as a microtubule-associated protein: structural and functional aspects","volume":"11","author":"Barbier","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"2024102910301110000_94.9.757.22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-12-85","article-title":"Ubiquitin carboxy-terminal hydrolase l1 (uch-l1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure","volume":"12","author":"Mondello","year":"2012","journal-title":"BMC Neurol"},{"key":"2024102910301110000_94.9.757.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"2024102910301110000_94.9.757.24","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517740641"},{"key":"2024102910301110000_94.9.757.25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"2024102910301110000_94.9.757.26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107"},{"key":"2024102910301110000_94.9.757.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"2024102910301110000_94.9.757.28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000978","article-title":"Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"8","author":"Marignier","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301110000_94.9.757.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep"},{"key":"2024102910301110000_94.9.757.30","doi-asserted-by":"crossref","first-page":"102785","DOI":"10.1016\/j.ebiom.2020.102785","article-title":"Blood biomarkers on admission in acute traumatic brain injury: relations to severity, CT findings and care path in the CENTER-TBI study","volume":"56","author":"Czeiter","year":"2020","journal-title":"EBioMedicine"},{"key":"2024102910301110000_94.9.757.31","unstructured":"Marshall WJ , Bangert SK . Clinical biochemistry: metabolic and clinical aspects. 2nd edition. Churchill Livingstone, 2008."},{"key":"2024102910301110000_94.9.757.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2012.06.002"},{"key":"2024102910301110000_94.9.757.33","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24554"},{"key":"2024102910301110000_94.9.757.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7169-7"},{"key":"2024102910301110000_94.9.757.35","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301110000_94.9.757.36","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318382"},{"key":"2024102910301110000_94.9.757.37","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1212\/WNL.0000000000008684","article-title":"Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders","volume":"94","author":"Ringelstein","year":"2020","journal-title":"Neurology"},{"key":"2024102910301110000_94.9.757.38","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000965","article-title":"Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein","volume":"8","author":"Hyun","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301110000_94.9.757.39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NFL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J Neuroinflammation"},{"key":"2024102910301110000_94.9.757.40","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200052","article-title":"Serum GFAP and NFL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-330412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:31:15Z","timestamp":1730208675000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-330412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jnnp-2022-330412"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-330412","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}